狼疮低疾病活动状态与系统性红斑狼疮患者直接医疗费用降低相关
该纵向队列研究纳入200例SLE患者(357.8人年),评估LLDAS与直接医疗费用的关联。多因素分析显示,观察期≥50%时间处于LLDAS与年直接医疗费用降低25.9%相关(P=0.04),而基线器官损害和糖皮质激素使用与费用增加相关。
要点
- 观察期≥50%时间处于LLDAS与年直接医疗费用降低25.9%相关(P=0.04)。
- 基线器官损害与费用增加41.7%相关(P=0.009)。
- 泼尼松>7.5-15 mg/天和>15 mg/天分别与费用增加55.7%(P=0.02)和202%(P<0.001)相关。
核心结论
- 更多时间处于LLDAS与SLE患者直接医院医疗费用显著降低相关。
研究设计与样本
- 单中心三级医院纵向SLE队列研究,纳入200例SLE患者,贡献357.8人年观察。
- 采用多因素线性回归分析LLDAS与直接医疗费用的关联。
主要发现
- 患者平均±标准差年直接医疗费用为7413±13133美元/年。
- 基线器官损害与费用增加41.7%相关(P=0.009)。
- 泼尼松>7.5-15 mg/天与费用增加55.7%相关(P=0.02),>15 mg/天与费用增加202%相关(P<0.001)。
- 观察期≥50%时间处于LLDAS与年直接医疗费用降低25.9%相关(P=0.04)。
关键数值与推荐
- LLDAS定义:SLEDAI-2K≤4且无新发活动,PhGA≤1,泼尼松≤7.5 mg/天,并使用最佳标准免疫抑制剂。
- 42%患者有狼疮肾炎病史,57.3%患者在研究开始时存在器官损害(SLICC/ACR损伤指数>0)。
临床怎么用
- 达标治疗中追求LLDAS可能不仅改善疾病结局,还有助于降低SLE患者的直接医疗费用。
- 控制基线器官损害和减少糖皮质激素用量可能对降低医疗费用有重要意义。
局限性
- 研究为单中心三级医院队列,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Treat-to-target end points for systemic lupus erythematosus (SLE) have been assessed for their impact on damage accrual and flare, but whether they have an impact on the high health care utilization and costs in SLE has not been studied. The purpose of this study was to examine our hypothesis that the recently described lupus low disease activity state (LLDAS) would be associated with reduced health care cost. METHODS: Data from a single tertiary hospital longitudinal SLE cohort were assessed. Baseline demographics, disease activity (Systemic Lupus Erythematosus Disease Activity Index 2000 [SLEDAI-2K], physician global assessment [PhGA], and flare index), and medication use were evaluated, and direct health care utilization and cost data were obtained from hospital information systems. LLDAS was defined as previously published: briefly, SLEDAI-2K ≤4 with no new activity, PhGA ≤1, prednisolone ≤7.5 mg/day, and optimal standard immunosuppressive agents. Analysis was performed using multivariable linear regression. RESULTS: Two hundred SLE patients, contributing 357.8 person-years of observation, were included. A history of lupus nephritis was present in 42% of patients, and damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index >0) was present at study commencement in 57.3% of patients. The mean ± SD annual direct medical cost per patient was US$7,413 ± 13,133/year. In multivariable analysis, increased cost was associated with the presence of baseline organ damage (41.7% increase; P = 0.009) and corticosteroid use (>7.5-15 mg/day: 55.7% increase; P = 0.02; and >15 mg/day: 202% increase; P < 0.001). In contrast, spending ≥50% of the observation period in LLDAS was associated with a 25.9% reduction in annual direct medical cost (P = 0.04). CONCLUSION: Greater time spent in LLDAS was associated with significantly reduced direct hospital health care costs among patients with SLE.
引用
- Yeo AL, Koelmeyer R, Kandane-Rathnayake R, et al. Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2020. PMID: 31282076. doi:10.1002/acr.24023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。